Revenues soar in 1Q for Merge eFilm

Article

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48 million in the previous year's quarter. Net income was $1.35 million compared with $1.32 million in 1Q 2003. Financial and operational gains reflected increasing popularity of the company's Fusion RIS/PACS. The company closed 17 deals for its Fusion RIS, PACS, or RIS/PACS during the quarter, increasing the total number of Fusion customers to 143, representing more than 290 healthcare facilities. Company executives anticipate continuing positive market conditions, with full-year 2004 guidance of 30% to 35% revenue growth year over year to a range of $37.5 to $39.5 million.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.